Mayzent

Showing 5 posts of 5 posts found.

Scottish Medicines Consortium gives go-ahead for Novartis’ Mayzent in secondary progressive multiple sclerosis

October 15, 2020
Sales and Marketing Mayzent, Novartis, Scotland

Novartis’ Mayzent (siponimod) has been approved by the Scottish Medicines Consortium in the treatment of secondary progressive multiple sclerosis (SPMS) …

NICE knocks back Novartis’ Mayzent in secondary progressive multiple sclerosis over data gaps

June 25, 2020
Sales and Marketing Mayzent, NHS, NICE, Novartis

Novartis’ Mayzent (siponimod) has been unsuccessful in securing a recommendation from NICE for use on the NHS for the treatment …

novartis_outside_1

Five-year data supports early treatment with Novartis’ Mayzent in secondary progressive multiple sclerosis

April 21, 2020
Manufacturing and Production, Research and Development Mayzent, Novartis, pharma

Novartis has pulled back the curtain on five-year data from an extension trial for its sphingosine 1-phosphate receptor modulator Mayzent …

mayzent

EMA advisory panel recommends Mayzent for secondary progressive multiple sclerosis

November 18, 2019
Sales and Marketing Europe, Mayzent, Novartis, multiple sclerosis, pharma

Novartis has revealed that Mayzent (siponimod) has been recommended by the European Medicines Agency’s (EMA) Committee for Medicinal Products for …

Novartis’ Mayzent delays time wheelchair dependence by 4 years in secondary progressive multiple sclerosis

September 12, 2019
Research and Development ECTRIMS 2019, Mayzent, Novartis, multiple sclerosis, pharma

Novartis has taken the opportunity at the 2019 Congress of The European Committee for Treatment and Research in Multiple Sclerosis …

Latest content